Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230571 | 1.00 | TACR1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9024421 | 1.00 | TACR1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8539276 | 1.00 | TACR1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2987770 | 1.00 | TACR1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9025699 | 1.00 | TACR1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9025317 | 0.99 | MEN1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4297874 | 0.99 | MEN1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9025323 | 0.99 | MEN1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8537738 | 0.99 | MEN1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8537737 | 0.99 | MEN1 (1.00) | TACR1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-20250082625-A1 | NOVEL THERAPY | SELECTIMMUNE PHARMA AB (SE) | 2025-03-13 | — | — | US | claimed |
| EP-2966448-B1 | METHOD FOR THE PREDICTION OR PROGNOSIS OF THE RESPONSE OF A HUMAN SUBJECT SUFFERING FROM CANCER TO TREATMENT WITH AN ANTAGONIST OF THE NK1 RECEPTOR | SERVICIO ANDALUZ DE SALUD (ES) | 2025-03-05 | — | — | EP | claimed |
| WO-2024194352-A1 | DEUTERATED P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-26 | — | — | WO | claimed |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-12 | — | — | US | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| EP-3481396-B1 | THERAPY OF BACTERIAL INFECTIONS. | SELECTIMMUNE PHARMA AB (SE) | 2023-05-31 | — | — | EP | claimed |
| EP-4103564-A1 | P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | claimed |
| CN-115413279-A | P2X3 modulators | 贝卢斯医疗咳嗽病公司 | 2022-11-29 | — | — | CN | claimed |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | claimed |
| US-20150224095-A1 | USE OF NON-PEPTIDIC NK1 RECEPTOR ANTAGONISTS FOR THE PRODUCTION OF APOPTOSIS IN TUMOR CELLS | NK-1 IP LIMITED (GB) | 2015-08-13 | — | — | US | claimed |
| EP-1803456-B1 | Pharmaceutical compositions comprising L-733060 for use in the treatment of cancer tumours | ANTAGONISTA ENEKAUNO S L (ES) | 2014-11-26 | — | — | EP | claimed |
| EP-1080080-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-07 | — | — | EP | claimed |
| EP-1080080-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999064000-A9 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999064000-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE NEUROKININ RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| EP-0600952-B1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK SHARP & DOHME (GB) | 1996-04-17 | — | — | EP | claimed |
| EP-0600952-A1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | MERCK SHARP & DOHME (GB) | 1994-06-15 | — | — | EP | claimed |
| WO-1993004040-A1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK SHARP & DOHME LIMITED (GB) | 1993-03-04 | — | — | WO | claimed |
| EP-0528495-A1 | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them | MERCK SHARP & DOHME LTD. (GB) | 1993-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | P2RX3, P2RX1, P2RX5 | TACR1 141/4885TP53 4616/4885CYP1A2 2455/4885 |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | TACR1 12/4885TP53 3729/4885CYP1A2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.